Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032637 | 0.89 | LMNA (0.52) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL15032502 | 0.88 | MAPT (0.51) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL10198368 | 0.86 | KMT2A (0.59) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL15032501 | 0.82 | MAPT (0.53) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL15032635 | 0.81 | ALDH1A1 (0.53) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL15032636 | 0.80 | SHMT2 (0.50) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL15032504 | 0.75 | ALDH1A1 (0.56) | KMT2AMAPTRAB9AALDH1A1GAA | |
| SCHEMBL855488 | 0.71 | HSD17B10 (0.48) | MEN1KMT2AALDH1A1GAAPOLB | |
| SCHEMBL741345 | 0.71 | HSD17B10 (0.46) | MEN1KMT2AALDH1A1GAA | |
| SCHEMBL16980495 | 0.68 | SMN1; SMN2 (0.61) | MEN1KMT2ATP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | TALDO1, PGD, DLD | MEN1 3731/4885KMT2A 2118/4885TP53 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.